| Raquel Renee Kacin, APN | |
|
247 Bluffs Ave, Bldg 1, Elko, NV 89801-2455 | |
| (775) 753-1049 | |
| (775) 777-8494 |
| Full Name | Raquel Renee Kacin |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 19 Years |
| Location | 247 Bluffs Ave, Elko, Nevada |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376647909 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163WG0000X | Registered Nurse - General Practice | RN25040 (Nevada) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | APRN000865 (Nevada) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| A Plus Urgent Care Llc | 2567686439 | 3 |
News Archive
Seaside Therapeutics, Inc. announced today data from the largest randomized, placebo-controlled study conducted to date in individuals with fragile X syndrome. In a Phase 2 study of STX209, clinically meaningful improvements on global and specific neurobehavioral outcomes were observed in the general study population. The improvements were statistically significant in pediatric patients with more severe impairments in sociability - a core symptom of fragile X syndrome.
Researchers from Mount Sinai School of Medicine, in collaboration with investigators of the National Institute of Health and Medical Research (INSERM) of France led by Nicolae Ghinea, PhD, have found a common link among several malignant tumor types in all grades of cancer. This breakthrough may ultimately provide a new diagnostic or therapeutic target to detect cancer early or stop tumor growth.
There is good accordance between spectral-domain and time-domain optical coherence tomography image assessments of eyes treated for neovascular age-related macular degeneration, show study findings.
Florida-based biopharmaceutical leader Oragenics, Inc. has appointed renowned international oral care authority Dr. Raman Bedi to serve as exclusive representative for the company's award-winning line of oral care products to the Middle East.
› Verified 5 days ago
| Entity Name | Pioneer Urgent Care & Family Med Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043499130 PECOS PAC ID: 7113906181 Enrollment ID: O20040714001475 |
News Archive
Seaside Therapeutics, Inc. announced today data from the largest randomized, placebo-controlled study conducted to date in individuals with fragile X syndrome. In a Phase 2 study of STX209, clinically meaningful improvements on global and specific neurobehavioral outcomes were observed in the general study population. The improvements were statistically significant in pediatric patients with more severe impairments in sociability - a core symptom of fragile X syndrome.
Researchers from Mount Sinai School of Medicine, in collaboration with investigators of the National Institute of Health and Medical Research (INSERM) of France led by Nicolae Ghinea, PhD, have found a common link among several malignant tumor types in all grades of cancer. This breakthrough may ultimately provide a new diagnostic or therapeutic target to detect cancer early or stop tumor growth.
There is good accordance between spectral-domain and time-domain optical coherence tomography image assessments of eyes treated for neovascular age-related macular degeneration, show study findings.
Florida-based biopharmaceutical leader Oragenics, Inc. has appointed renowned international oral care authority Dr. Raman Bedi to serve as exclusive representative for the company's award-winning line of oral care products to the Middle East.
› Verified 5 days ago
| Entity Name | A Plus Urgent Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073939609 PECOS PAC ID: 2567686439 Enrollment ID: O20140616000894 |
News Archive
Seaside Therapeutics, Inc. announced today data from the largest randomized, placebo-controlled study conducted to date in individuals with fragile X syndrome. In a Phase 2 study of STX209, clinically meaningful improvements on global and specific neurobehavioral outcomes were observed in the general study population. The improvements were statistically significant in pediatric patients with more severe impairments in sociability - a core symptom of fragile X syndrome.
Researchers from Mount Sinai School of Medicine, in collaboration with investigators of the National Institute of Health and Medical Research (INSERM) of France led by Nicolae Ghinea, PhD, have found a common link among several malignant tumor types in all grades of cancer. This breakthrough may ultimately provide a new diagnostic or therapeutic target to detect cancer early or stop tumor growth.
There is good accordance between spectral-domain and time-domain optical coherence tomography image assessments of eyes treated for neovascular age-related macular degeneration, show study findings.
Florida-based biopharmaceutical leader Oragenics, Inc. has appointed renowned international oral care authority Dr. Raman Bedi to serve as exclusive representative for the company's award-winning line of oral care products to the Middle East.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Raquel Renee Kacin, APN 40 Burton Hills Blvd, Suite 200, Nashville, TN 37215-6155 Ph: (615) 565-1733 | Raquel Renee Kacin, APN 247 Bluffs Ave, Bldg 1, Elko, NV 89801-2455 Ph: (775) 753-1049 |
News Archive
Seaside Therapeutics, Inc. announced today data from the largest randomized, placebo-controlled study conducted to date in individuals with fragile X syndrome. In a Phase 2 study of STX209, clinically meaningful improvements on global and specific neurobehavioral outcomes were observed in the general study population. The improvements were statistically significant in pediatric patients with more severe impairments in sociability - a core symptom of fragile X syndrome.
Researchers from Mount Sinai School of Medicine, in collaboration with investigators of the National Institute of Health and Medical Research (INSERM) of France led by Nicolae Ghinea, PhD, have found a common link among several malignant tumor types in all grades of cancer. This breakthrough may ultimately provide a new diagnostic or therapeutic target to detect cancer early or stop tumor growth.
There is good accordance between spectral-domain and time-domain optical coherence tomography image assessments of eyes treated for neovascular age-related macular degeneration, show study findings.
Florida-based biopharmaceutical leader Oragenics, Inc. has appointed renowned international oral care authority Dr. Raman Bedi to serve as exclusive representative for the company's award-winning line of oral care products to the Middle East.
› Verified 5 days ago
Suzanne Windous, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1995 Errecart Blvd Ste 200, Elko, NV 89801 Phone: 775-340-2051 | |
Elizabeth Jean Burlew, A.P.R.N. Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1775 Browning Way, Ste 104, Elko, NV 89801 Phone: 775-738-5100 Fax: 775-738-5115 | |
Dr. Irene R Wolf, DNP, APRN, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1810 Pinion Rd, Elko, NV 89801 Phone: 775-753-7387 Fax: 775-738-4918 | |
Janine Anderson, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1995 Errecart Blvd Ste 204, Elko, NV 89801 Phone: 775-748-0704 Fax: 775-738-7641 | |
Jane Owen, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3740 E Idaho St, Elko, NV 89801 Phone: 775-738-8004 | |
Dr. Allyson C Waldron, DNP, APRN, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1993 Errecart Blvd, Elko, NV 89801 Phone: 775-753-1049 Fax: 775-777-8494 | |
Iona Michelle Weeks, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1993 Errecart Blvd., Elko, NV 89801 Phone: 775-753-1049 Fax: 775-777-8494 |